Cerebellar toxicity following high-dose cytosine arabinoside.
- 1 May 1985
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 3 (5) , 613-616
- https://doi.org/10.1200/jco.1985.3.5.613
Abstract
A patient with acute cerebellar toxicity following systemic high-dose cytosine arabinoside (ara-C) 3 g/m2/12 h for secondary acute nonlymphocytic leukemia is reported. Initial symptoms of ataxia and dysarthria emerged at 30 g/m2 cumulative dose and persisted without improvement over a 10 wk period. Recurrence and worsening of cerebellar symptoms followed further consolidation treatment with high-dose ara-C. Subsequent autopsy showed extensive Purkinje''s cell damage in the lateral cerebellar hemispheres. Persistent severe toxicity can occur at total doses less than those generally recognized.This publication has 5 references indexed in Scilit:
- Acute cerebellar dysfunction with high-dose ARA-C therapyCancer, 1983
- HIGH-DOSE CYTOSINE-ARABINOSIDE THERAPY FOR REFRACTORY LEUKEMIA1983
- A PILOT-STUDY OF HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE FOR ACUTE-LEUKEMIA AND REFRACTORY LYMPHOMA - CLINICAL-RESPONSE AND PHARMACOLOGY1982
- Central nervous system toxicity of high-dose systemic cytosine arabinosideCancer, 1981
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979